报告期内，公司心胸外科业务实现营业收入1,424.46万元，其中PEEK材料胸骨固定带实现销售收入1,367.01万元，较上年同期增长83.39%。PEEK材料胸骨固定产品在全国各省市入院招标及市场推广工作的开展顺利，使该产品销售收入保持较高增速。未来伴随PEEK材料产品渗透率的提升，心胸外科业务收入规模预计将持续增加。Kangtuo Medical (688314.SH) disclosed its 2023 annual report, and the company achieved revenue of 2 in 2023...
According to Zhitong Finance App News, Kangtuo Healthcare (688314.SH) disclosed its 2023 annual report. The company achieved revenue of 275 million yuan in 2023, an increase of 14.62% over the previous year; net profit to mother of 75.51 million yuan, a year-on-year decrease of 0.23%; after deducting non-net profit of 68.35 million yuan, an increase of 0.56% over the previous year; and basic earnings per share of 0.93 yuan. The company plans to distribute a cash dividend of 3.2 yuan (tax included) for every 10 shares to all shareholders.
During the reporting period, the company's neurosurgical PEEK materials and titanium products achieved operating revenue of 243.6939 million yuan, an increase of 11.88% over the same period last year. The above business accounted for 92.79% of the main business revenue. In the neurosurgery business, PEEK material products achieved revenue of 166.894 million yuan, an increase of 18.01% over the same period of the previous year. The share of revenue in the main business revenue increased to 63.55%, an increase of 1.95 percentage points over the same period last year. Titanium neurosurgical products achieved revenue of 76.7945 million yuan, an increase of 0.53% over the same period last year.
During the reporting period, the company's cardiothoracic surgery business achieved revenue of 14.244,600 yuan, of which PEEK sternum braces achieved sales revenue of 13.6701 million yuan, an increase of 83.39% over the same period last year. The PEEK sternum fixation product is progressing smoothly in admissions tenders and marketing work in all provinces and cities across the country, keeping the sales revenue of this product at a high growth rate. In the future, along with the increase in the penetration rate of PEEK material products, the revenue scale of the cardiothoracic surgery business is expected to continue to increase.
During the reporting period, the company's other products, such as dental products, absorbable skull repair, maxillofacial repair products and supporting surgical tools, achieved a total revenue of 4.6893 million yuan, an increase of 36.25% over the same period last year. The revenue scale of the above products is small, mainly due to the short product launch cycle and the synergy effects have not yet been released. The company has gradually increased investment in promoting products with strong competitiveness and high synergy, and increased the revenue scale of these products.
